Investigators evaluate the performance of the G6 factory-calibrated continuous glucose monitoring system over 10 days.
The new Flash Glucose Monitoring System enables patients to wear the sensor for up to 14 days compared with the existing FreeStyle Libre System that was approved for 10-day wear.
Researchers conducted a randomized, open-label trial to assess the effect of an automated closed-loop insulin delivery system on glycemic control in hospitalized patients.
Patients were randomly assigned to receive insulin aspart or Technosphere inhaled insulin.
In children with type 1 diabetes, the Omnipod hybrid closed-loop personal model system was safe and performed well.
The ITCA 650, a small titanium osmotic mini-pump, provides a subcutaneous infusion of exenatide over 3 or 6 months.
Participants completed surveys for fear of hypoglycemia, hypoglycemia unawareness, and problem areas in diabetes questionnaire.
The safety assessment included incidence of insertion or procedure-related removal and device-related serious adverse events through 180 after insertion.
The sensor is coated with a fluorescent chemical which produces a small amount of light when exposed to blood glucose.
The Omnipod DASH system consists of a discreet, tubeless, waterproof Pod which is worn on the body, and the Personal Diabetes Manager (PDM), a handheld wireless device used to control the Pod.
The FDA reviewed data for the device through the de novo premarket review pathway, a regulatory pathway for novel, low-to-moderate-risk devices that are not substantially equivalent to an already legally marketed device.
Interpreting trend arrow data from continuous glucose monitoring may provide additional data to improve glycemic control in adults with diabetes mellitus.
Professional continuous glucose monitoring can significantly reduce the economic burden of type 2 diabetes.
Secure messaging presents an opportunity for patients and healthcare providers to collaborate on self-management issues like glycemic control, diet, and exercise.
New monitoring system involves the placement of a small sensor wire beneath the skin surface to continuously monitor glucose levels.
Machines were used to examine the glycemic impact of various meals to determine a glucose forecast.
The studies will assess the safety, efficacy, and user-friendliness among other aspects, of multiple artificial pancreas devices.
The FDA's expanded indication for the Dexcom G5 Continuous Glucose Monitoring System allows for replacement of fingerstick glucose testing.
The system allows patients and their caregivers to access glucose measurements through their pump or through a mobile app.
The Contour®Next One Blood Glucose Management System will be available in early 2017.
An implantable continuous glucose monitor appears to be a safe and effective alternative to a transcutaneous monitor in diabetes.
FDA approval of the first closed-loop insulin delivery system is exciting for both physicians and patients. What does this mean for the future?
The FDA is coordinating with investigators, manufacturers, clinicians, and others to bring automated insulin delivery devices to market.
The paper raises questions regarding safety for measuring blood glucose, and when blood glucose meters are used in trials.
The FDA has approved the Animas Vibe insulin pump and continuous glucose monitoring system for patients with diabetes.
Roche announced the launch of Accu-Chek Aviva Expert system, the first blood glucose meter with a built-in insulin calculator.
Endocrinology Advisor Articles
- Diet Quality and Glycemic Control in Women With Gestational Diabetes
- Most Foods Containing Fructose Do Not Have Harmful Effect on Glycemic Control
- Hypothyroidism Treatment No Longer Available
- Endocrine-Disrupting Chemicals in Personal Care Products Linked to Early Puberty
- Serious Adverse Events Linked to SGLT2 Inhibitors
- Hypertensive Disorders in Pregnancy, Postpartum BMI Linked to T2D Risk
- Sleep Quality, Duration Affect Risk for Falls and Fractures in Older Women
- Physician Burnout Linked to Stress in Using Health Information Technology
- Type 2 Diabetes Linked to Colorectal Cancer Risk in Men
- Urinary Incontinence Drug May Reduce Frequency of Hot Flashes